SNBP Sinobiopharma, Inc. featured news, full reports, and detailed charts
Sinobiopharma, Inc. (SNBP/SNBP.OB) Wrap Up:
Sinobiopharma, Inc. engages in the research, production, and development of biopharmaceutical products in China. The company is based in Nantong City, China.www.sinobiopharma.com
100 Employees
Sinobiopharma, Inc. (SNBP:OTC Bulletin Board Market)
LAST $0.26 USD
CHANGE TODAY +0.03 13.04%
VOLUME 1.3M
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Sinobiopharma, Inc. (SNBP)
|
OPEN
$0.24
|
PREVIOUS CLOSE
$0.23
|
|
|
DAY HIGH
$0.28
|
DAY LOW
$0.24
|
|
|
52 WEEK HIGH
01/23/09 - $1.50
|
52 WEEK LOW
09/30/09 - $0.15
|
|
|
MARKET CAP
20.8M
|
AVERAGE VOLUME 3 mo
1.6M
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
80.0M
|
|
|
SNBP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SNBP Top Compensated Officers
Dr. Lee Huang Lequn
Chairman of the Board, Chief Executive Office...
Age: 54
Total Annual Compensation: --
Mr. Jianguo Wang
Secretary and Director
Age: 49
Total Annual Compensation: --
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for Sinobiopharma, Inc. (SNBP)
Sinobiopharma Inc. Reports Unaudited Financial Results for the First Quarter Ended August 31, 2009
10/21/2009
Sinobiopharma Inc. reported unaudited financial results for the first quarter ended August 31, 2009. For the quarter, the company's revenue increased to $1,293,764 from $931,203 a year ago, an increase of 39%. Gross profit increased 57% to $962,923, reflecting a 74% gross margin against $612,428, and a 66% gross margin, a year ago. With a net profit of $237,167 the quarter marks the first time the company has moved from loss to net profitability. The main expense affecting the net result was a stock-based compensation charge of $324,125. Growth in sales and the improvement in gross margin were both due to continued strong demand for of Cisatracurium Besylate, which contributed $1,240,405, or 96% of revenue ups from $865,407 a year ago.
Sinobiopharma Inc. Announces Change of Auditors; Announces Management Changes
09/29/2009
On September 25, 2009, the Board of Directors of Sinobiopharma Inc. approved and authorized the dismissal of Schumacher & Associates Inc., its independent registered public accounting firm. On the same date, the Board of Directors approved and authorized the appointment and engagement of the accounting firm of Bernstein & Pinchuk LLP as the company's new independent registered public accounting firm. On September 25, 2009, Mr. Martin Shen resigned as a director of the company for personal reasons. In addition, on the same date, Dr. Lequn Lee Huang resigned as the CFO of the company in order to allow for the appointment of a new CFO for the company. On the same date, Mr. Xinjie (James) Mu was appointed as a director of the company to fill the vacant director position. In addition, Mr. Mu was appointed as the new CFO of the company. Mr. Xinjie (James) Mu (age 39) has been an independent consultant from January 2008 to present and since March 9, 2008, Mr. Mu has been a director of China Infrastructure Investment Corporation.
Sinobiopharma Inc. Reports Audited Earnings Results for the Fiscal Year Ended May 31, 2009
09/23/2009
Sinobiopharma Inc. reported audited earnings results for the fiscal year ended May 31, 2009. For the year, the company reported sales revenue increased to $3,850,278 from $1,810,318 in the corresponding period ended May 31, 2008, a year-over-year increase of 112.69%. Gross profit increased to $2,538,441, representing 66% of sales revenue, for the 12 months ended May 31, 2009, from $580,915, representing 32% of revenue, in the corresponding period ended May 31, 2008. Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate, a pre-surgical skeletal muscle relaxant.
SNBP Competitors
| Company | Last | Change |
| GlaxoSmithKline | 1,254 GBX | +13.00 |
| Jiangsu Hengrui Medicine Co Ltd | ¥47.87 CNY | +0.11 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SNBP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.4x |
|
| Price/Book | 13.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.3x |
|
|
SNBP |
||
|
SNBP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Sinobiopharma, Inc.
More news for SNBP
Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
NANTONG CITY, China, Oct. 21 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OCT Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to present the following highlights from the unaudited financial results for the first quarter ended August 31, 2009. The highlights feature record revenues and increases in both gross margin and net profit, and a Company milestone of posting its first overall net profitable quarter since the second quarter 2008, according to Dr. Lequn Lee Huang, Sinobiopharma President and CEO. -- Revenue increased to US $1,293,764 for the three months ended August 31, 2009 from US $931,203 in the corresponding period ended August 31, 2008, an increase of 39%. -- Gross profit increased 57% to US $962,923, reflecting a 74% gross margin for the three months ended August 31, 2009. This compares to US $612,428, and a 66% gross margin, reported for the corresponding period ended August 31, 2008. -- Net profit of the Company's wholly owned operating subsidiary, Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., increased to US $561,292, representing 43% of sales revenue, for the three months ended August 31, 2009 from US $218,031 in the corresponding period ended August 31, 2008, a year-over-year increase of more than 154%. -- With a net profit overall of US $237,167 for the three months ended August 31, 2009, the quarter marks the first time Sinobiopharma has moved from loss to net profitability. During the quarter, the main expense affecting the net result was a stock-based compensation charge of US $324,125. The charge has been fully amortized in this quarter, reflecting the vesting of stock options granted by the Company. -- Growth in sales and the improvement in gross margin were both due to ...Click here to read the whole Article (external link)
SINOBIOPHARMA, INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
SINOBIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
ITEM 2 . MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following plan of operation together with our financial statements and related notes appearing elsewhere in this quarterly report. This plan of operation contains forward-looking statements that involve risks, uncertainties, and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. Overview The Company, through its operating subsidiary Dong Ying China, is involved in the Chinese biopharmaceutical industry. We are engaged in the research, development, manufacture and marketing of biopharmaceutical products in China. The company has developed new methods for synthesis of active pharmaceutical ingredient ("API") and innovative drug delivery (new formulation) that dramatically reduces the time and cost of drug development. Our current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Our R&D focus is new, innovative methods of synthesizing compounds more rapidly at lower cost, and/or improved drug formulation with enhanced usability. Results of Operations The Company realized a net income of $237,167 for the three months ended August 31, 2009, as compared to $147,863 for the three months ended August 31, 2008. Sales revenues and cost of sales Sales revenue increased 39% to $1,293,764 for the three months ended August 31, 2009, from $931,203 for the three months ended August 31, 2008. Gross profit increased 57% to $962,923 (74% of sales revenue) for the three months ended August 31, 2009, from $612,428 (66% of revenue) for the three months ended August 31, 2008. The increase in sales volume and the improvement in gross margin are both due to growth in sales of Cisatracurium Besylate. Sales of this product increased to $1,240,405 for the three months ended August 31, 2009, from $865,407 for the three ...Click here to read the whole Article (external link)
Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP - News; "Sinobiopharma") (the "Company") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA"). Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.The Company is now awaiting GMP certification to manufacture Gabexate mesylate.About SinobiopharmaSinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.FORWARD LOOKING STATEMENTSThis news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United ...Click here to read the whole Article (external link)
Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board
NANTONG CITY, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP - News; ''Sinobiopharma'' or, the ''Company'') is pleased to announce that it has appointed Mr. Xinjie (James) Mu as the new Chief Financial Officer and as a director on the Board. Dr. Lequn Huang resigned as the Chief Financial Officer in order to make room for the appointment of Mr. Mu. Mr. Mu has more than twelve years experience in the financial field. Most recently, Mr. Mu has been an independent consultant working for China based US public companies. Prior to that, he was a Chief Financial Officer at Jingwei International Limited (OTCBB: JNGW.OB - News). Prior to that, he served as a senior accountant at Geller and Company in New York City. Mr. Mu is also a Director of China Infrastructure Investment Corporation (NASDAQ: CIIC - News) since March 2008....Click here to read the whole Article (external link)
Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
NANTONG CITY, China, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or the "Company") is pleased to report financial highlights from the audited financial results for the fiscal year ended May 31, 2009. Financial highlights include: -- Sales revenue increased to US$3,850,278 for the 12 months ended May 31, 2009, from US$1,810,318 in the corresponding period ended May 31, 2008, a year-over-year increase of 112.69 percent. -- Gross profit increased to US$2,538,441, representing 66 percent of sales revenue, for the 12 months ended May 31, 2009, from US$580,915, representing 32 percent of revenue, in the corresponding period ended May 31, 2008. -- Net profit of the Company's wholly owned operating subsidiary, Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., increased to US$1,019,507 representing 26% of sales revenue, for the 12 months ended May 31, 2009, from -US$199,306 in the corresponding period ended May 31, 2008, a year-over-year increase of more than 400 percent. However, the Company's overall net loss increased to US$2,140,237 for the 12 months ended May 31, 2009, of which one of the main expenses affecting the results of operations was the stock-based compensation charge of US$2,917,125, reflecting the vesting of stock options granted by the Company and professional fee of public company administration (audit, legal, etc.) of US$270,518. -- Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate, a pre- surgical skeletal muscle relaxant. Sales of this product increased to US$3,595,031 in the 12 months ended May 31, 2009, from US$1,364,165 in the 12 months ended May 31, 2008. At the same time,...Click here to read the whole Article (external link)
Emissary Capital Group Initiates Coverage on Sinobiopharma
NEW YORK, Sept. 21 /PRNewswire/ -- Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board: SNBP - News) with a Buy rating and target price of $1.00-$1.25. Jiangsu, China-based SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products. The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and cardiovascular-related products related to high blood pressure (commercial in October 2009). KuTai, SNBP's flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures. The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University. About Emissary Capital GroupEmissary Capital Group, Inc. is a New York City-based company that provides strategic consulting and research services to emerging growth companies primarily based in India and China. The firm provides a diversified array of services to small and medium s...Click here to read the whole Article (external link)
Would you like to leave a comment about Sinobiopharma, Inc. SNBP/SNBP.OB
Find out what social network information about Sinobiopharma, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Sinobiopharma, Inc. there is more great information available at Realpennies.com